First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (NASDAQ:TRAXV) — Market Cap & Net Worth
Market Cap & Net Worth: First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (TRAXV)
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued (NASDAQ:TRAXV) has a market capitalization of $559.11 Million ($559.11 Million) as of May 29, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11947 globally and #2912 in its home market, demonstrating a -9.56% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's stock price $16.09 by its total outstanding shares 34748841 (34.75 Million). Review First Tracks Biotherapeutics, Inc. Ordin PP&E and investment ratio to measure how much of shareholders' equity is committed to strategic physical and investment assets.
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Market Cap History: 2026 to 2026
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's market capitalization history from 2026 to 2026. Data shows growth from $559.11 Million to $559.11 Million (0.00% CAGR).
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of TRAXV by Market Capitalization
Companies near First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued in the global market cap rankings as of May 29, 2026.
Key companies related to First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #422 globally with a market cap of $64.67 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #585 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #606 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $437.22 |
| #422 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.67 Billion | $627.74 |
| #585 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #606 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued Historical Marketcap From 2026 to 2026
Between 2026 and today, First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued's market cap moved from $559.11 Million to $ 559.11 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $559.11 Million | -- |
End of Day Market Cap According to Different Sources
On May 28th, 2026 the market cap of First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $559.11 Million USD |
| MoneyControl | $559.11 Million USD |
| MarketWatch | $559.11 Million USD |
| marketcap.company | $559.11 Million USD |
| Reuters | $559.11 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About First Tracks Biotherapeutics, Inc. Ordinary Shares When-Issued
First Tracks Biotherapeutics, Inc. operates as a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. First Tracks Biotherapeutics, Inc. was formerly known as Biopharma Co., Inc. and changed its name to First Tracks Biotherapeutics, Inc. in February 2026. First Tracks Biotherapeutics, Inc. was incor… Read more